Tumors of the meninges

Handbook of Clinical Neurology

Volumn 105, Issue , 2012, Pages 641-656

  Viswanathan, Ashwin ^a   Demonte, Franco ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855528746     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53502-3.00014-8     Document Type: Chapter

References (97)

1. Al-Mefty O. Clinoidal meningiomas. meningiomas 1991, 427-443. Raven Press, New York. O. Al-Mefty (Ed.).
2. Al-Mefty O., Smith R.R. Tuberculum sellae meningiomas. meningiomas 1991, 397-398. Raven Press, New York. O. Al-Mefty (Ed.).
3. Al-Mefty O., Fox J.L., Smith R.R. Petrosal approach for petroclival meningiomas. Neurosurgery 1988, 22:510-517.
4. Al-Mefty O., Kersh J.E., Routh A., et al. The long-term side effects of radiation therapy for benign brain tumors in adults. J Neurosurg 1990, 73:502-512.
5. Al-Mefty O., Topsakal C., Pravdenkova S., et al. Radiation-induced meningiomas: clinical, pathological, cytokinetic, and cytogenic characteristics. J Neurosurg 2004, 100:1002-1013.
6. Annegers J.F., Laws E.R., Kurland L.T., et al. Head trauma and subsequent brain tumors. Neurosurgery 1979, 4:203-206.
7. Artlich A., Schmidt D. Immunohistochemical profile of meningiomas and their histological subtypes. Hum Pathol 1990, 21:843-849.
8. Barbaro N.M., Gutin P.H., Wilson C.B., et al. Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery 1987, 20:525-528.
9. Bruna J., Brell M., Ferrer I., et al. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 2007, 27:114-120.
10. Buhl R., Wolff S., Hugo H.H., et al. MR spectroscopy in patients with intracranial meningiomas. Neurol Res 2007, 29:43-46.
11. Cappabianca P., Maiuri F., Pettinato G., et al. Hemangiopericytoma of the spinal canal. Surg Neurol 1981, 15:298-302.
12. Cargioli T.G., Ugur H.C., Ramakrishna N., et al. Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. Neurosurgery 2007, 60:750-760.
13. CBTRUS Statistical Report: Primary Brain Tumors in the United States, 1998-2002 2005, Central Brain Tumor Registry of the United States, Chicago, IL.
14. Chamberlain M.C., Tsao-Wei D.D., Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology 2004, 62:1210-1212.
15. Chamberlain M.C., Tsao-Wei D.D., Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol 2006, 78:271-276.
16. Christensen H.C., Schüz J., Kosteljanetz M., et al. Cellular telephones and risk for brain tumors: a population-based, incident case-control study. Neurology 2005, 64:1189-1195.
17. Condra K.S., Buatti J.M., Mendenhall W.M., et al. Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 1997, 39:427-436.
18. Cushing H., Eisenhardt L. Meningiomas: Their Classification, Regional Behaviour, Life History, and Surgical End Results 1938, Charles C Thomas, Springfield, IL.
19. Debus J., Wuendrich M., Pirzkall A., et al. High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol 2001, 19:3547-3557.
20. DeMonte F., Al-Mefty O. Neoplasms and the cranial nerves of the posterior fossa. Surgery of the Cranial Nerves of the Posterior Fossa 1993, 253-274. American Association of Neurological Surgeons, Park Ridge, IL. D.L. Barrow (Ed.).
21. Drummond K.J., Zhu J., Black P.M. Meningiomas: updating basic science, management and outcome. Neurologist 2004, 10:113-130.
22. Dufour H., Metellus P., Fuentes S., et al. Meningeal hemangiopericytoma: a retrospective study of 21 patients with special review of postoperative external radiotherapy. Neurosurgery 2001, 48:756-762.
23. Ecker R.D., Marsh W.R., Pollock B.E., et al. Hemangiopericytoma in the central nervous system: treatment, pathological features, and long-term follow up in 38 patients. J Neurosurg 2003, 98:1182-1187.
24. Fanning E. Simian virus 40 large T antigen: the puzzle, the pieces, and the emerging picture. J Virol 1992, 66:1289-1293.
25. Gautier-Smith C., Lamouche M. Parasagittal and Falx Meningiomas 1970, Butterworths, London.
26. Glaholm J., Bloom H.J.G., Crow J.H. The role of radiotherapy in the management of intracranial meningiomas: the Royal Marsden Hospital experience with 186 patients. Int J Radiat Oncol Biol Phys 1990, 18:755-761.
27. Goellner J.R., Laws E.R., Soule E.H., et al. Hemangiopericytoma of the meninges. Mayo Clinic experience. Am J Clin Pathol 1978, 70:375-380.
28. Goldsmith B.J., Wara W.M., Wilson C.B., et al. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 1994, 80:195-201.
29. Grunberg S., Weiss M., Spitz I., et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991, 74:861-866.
30. Gupta V., Su Y.S., Samuelson C.G., et al. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg 2007, 106:455-462.
31. Guthrie B.L., Ebersold M.J., Scheithauer B.W., et al. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 1989, 25:514-522.
32. Gutmann D.H., Donohoe J., Perry A., et al. Loss of DAL-1 a protein 4.1-related tumor suppressor is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000, 9:1495-1500.
33. Hansson C.M., Buckley P.G., Grigelioniene Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. BMC Genomics 2007, 8:16.
34. Hentschel S.J., DeMonte F. Olfactory groove meningiomas. Neurosurg Focus 2003, 14:e4.
35. Henzel M., Gross M., Hamm K., et al. Significant tumor volume reduction of meningiomas after stereotactic radiotherapy: results of a prospective multicenter study. Neurosurgery 2006, 59:1188-1194.
36. Holmes G., Sargent P. Suprasellar endotheliomata. Brain 1927, 50:518-537.
37. Hsu D.W., Efird J.T., Hedley-White E.T. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 1997, 86:113-120.
38. Inskip P.D., Mellemkjaer L., Gridley G., et al. Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control 1998, 9:109-116.
39. Jalali R., Loughrey C., Baumert B., et al. High precision focused irradiation in the form of fractionated stereotactic radiotherapy (SCRT) for benign meningiomas predominantly in the skull base location. Clin Oncol (R Coll Radiol) 2002, 14:103-109.
40. Kaba S.E., DeMonte F., Bruner J.M., et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997, 40:271-275.
41. Katzman G.L. Meningioma. Diagnostic Imaging Brain, Section II(4) 2004, 56-63. Amirsys, Salt Lake City, UT. A. Osborn (Ed.).
42. Kinjo T., Al-Mefty O., Kanaan I. Grade zero removal of supratentorial convexity meningiomas. Neurosurgery 1993, 33:394-399.
43. Kochanek S., Schroder R., Firsching R. Hemangiopericytoma of the meninges. I Histopathological variability and differential diagnosis. Zentralbl Neurochir 1986, 47:183-190.
44. Krenkel W., Frowein R.A. Suprasellar meningiomas. Acta Neurochir (Wein) 1975, 31:280-287.
45. Kruse F. Hemangiopericytoma of the meninges (angioblastic meningioma of Cushing and Eisenhardt). Clinicopathologic aspects and follow-up studies in 8 patients. Neurology 1961, 11:771-777.
46. Lamszus K. Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 2004, 63:275-286.
47. Lanman T.H., Backer D.P. Falcine meningiomas. meningiomas 1991, 345-356. Raven Press, New York. O. Al-Mefty (Ed.).
48. Loven D., Hardoff R., Sever Z.B., et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 2004, 67:221-226.
49. Lusis E.A., Chicoine M.R., Perry A. High throughput screening of meningioma biomarkers using a tissue microarray. J Neurooncol 2005, 73:219-223.
50. MacCarty C., Taylor W. Intracranial meningiomas: experiences at the Mayo Clinic. Neurol Med Chir (Tokyo) 1979, 19:569-574.
51. Majos C., Alonsa J., Aguilera C. Utility of proton MR spectroscopy in the diagnosis of radiologically atypical intracranial meningiomas. Neuroradiology 2003, 45:129-136.
52. Matsuda Y., Kawamoto K., Kiya K., et al. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 1994, 80:527-534.
53. Matsuno A., Hiroshi N., Nagashima T. Histopathological analysis and proliferative potentials of intracranial meningiomas using bromodeoxyuridine and MIB-1 immunohistochemistry. Acta Histochem Cytochem 2005, 38:9-15.
54. Miralbell R., Linggood R.M., De la Monte S., et al. The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 1992, 13:157-164.
55. Mirimanoff R.O., Dosoretz D.E., Linggood R.M., et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985, 62:18-24.
56. Monteiro G.T., Pereira R.A., Kiofman R.J., et al. Head injury and brain tumors in adults: a case-control study in Rio de Janeiro, Brazil. Eur J Cancer 2006, 42:917-921.
57. Newton H., Slivka M., Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 2000, 49:165-170.
58. Nunnery E.W., Kahn L.B., Reddick E.L., et al. Hemangiopericytoma: a light microscopic and ultrastructural study. Cancer 1981, 47:906-914.
59. Perry A., Scheithauer B.W., Stafford S.I., et al. "Rhabdoid" meningioma: an aggressive variant. Am J Surg Pathol 1998, 22:1482-1490.
60. Perry A., Scheithauer B.W., Stafford S.I., et al. "Malignancy" in meningiomas: a clinicopathological study of 116 patients, with grading implications. Cancer 1999, 85:2046-2056.
61. Perry A., Louis D.N., Scheithauer B.W., et al. Meningiomas. World Health Organization Classification of Tumors 2007, 164-172. IARC Press, Lyons, Pathology and Genetics of Tumors of the Nervous Systems. P. Kleihues, W.K. Cavanee (Eds.).
62. Phillips L.E., Koepsell T.D., van Belle G., et al. History of head trauma and risk of intracranial meningioma: population-based case-control study. Neurology 2002, 58:1849-1852.
63. Pitkethly D.T., Hardman J.M., Kempe L.G., et al. Angioblastic meningiomas. Clinicopathologic study of 81 cases. J Neurosurg 1970, 32:539-544.
64. Pollock B.E., Stafford S.L., Utter A., et al. Stereotactic radiosurgery provides equivalent tumor control to Simpson grade 1 resection for patients with small- to medium-size meningiomas. Int J Radiat Oncol Biol Phys 2003, 55:1000-1005.
65. Pravdenkova S., Al-Mefty O., Sawyer J., et al. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg 2006, 105:163-173.
66. Preston-Martin S., Paganini-Hill A., Henderson B.E., et al. Case-control study of intracranial meningiomas in women in Los Angeles County, California. J Natl Cancer Inst 1980, 65:67-73.
67. Preston-Martin S., Yu M.C., Henderson B.E., et al. Risk factors for meningiomas in men in Los Angeles County. J Natl Cancer Inst 1983, 70:863-866.
68. Preston-Martin S., Pogoda J.M., Schlehofer B., et al. An international case-control study of adult glioma and meningioma: the role of head trauma. Int J Epidemiol 1998, 27:579-586.
69. Probst-Cousin S., Bergmann S., Schroder R., et al. Ki-67 and biological behaviour in meningeal hemangiopericytomas. Histopathology 1996, 29:57-61.
70. Quest D. Meningiomas: an update. Neurosurgery 1978, 3:219-225.
71. Ragel B.T., Gillespie D.L., Kushnir V., et al. Calcium channel antagonists augment hydroxyurea- and RU486-induced inhibition of meningioma growth in vivo and in vitro. Neurosurgery 2006, 59:1109-1121.
72. Ribalta T., McCutcheon I., Aldape K., et al. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 2004, 28:1532-1536.
73. Riemenschneider M., Perry A., Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006, 5:1045-1054.
74. Rohringer M., Sutherland G.R., Louw D.F., et al. Incidence and clinicopathological features of meningioma. J Neurosurg 1989, 71:665-672.
75. Rollison D.E., Page W.F., Crawford H., et al. Case-control study of cancer among US Army veterans exposed to simian virus 40-contaminated adenovirus vaccine. Am J Epidemiol 2004, 160:317-324.
76. Ron E., Modan B., Boice J.D., et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 1988, 319:1033-1039.
77. Rubinstein A.B., Loven D., Geier A., et al. Hormone receptors in initially excised versus recurrent intracranial meningiomas. J Neurosurg 1994, 81:184-187.
78. Salzman K.L. Meningioma. Diagnostic Imaging Brain, Section I(6) 2004, 118-121. Amirsys, Salt Lake City, UT. A. Osborn (Ed.).
79. Schnitt S.J., Vogel H. Meningiomas. Diagnostic value of immunoperoxidase staining for epithelial membrane antigen. Am J Surg Pathol 1986, 10:640-649.
80. Schüz J., Böhler E., Berg G., et al. Cellular phones, cordless phones, and the risks of glioma and meningioma (Interphone Study Group, Germany). Am J Epidemiol 2006, 163:512-520.
81. Sekhar L.N., Jannetta P.J. Cerebellopontine angle meningiomas: microsurgical excision and follow-up results. J Neurosurg 1984, 60:500-505.
82. Shintani T., Hayakawa N., Hoshi M., et al. High incidence of meningioma among Hiroshima atomic bomb survivors. J Radiat Res 1999, 40:40-57.
83. Simon M., Bostrom J.P., Hartmann C. Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery 2007, 60:787-798.
84. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957, 20:22-39.
85. Sloof J., Kernohan J., MacCarthy C. Primary Intramedullary Tumors of the Spinal Cord and Filum Terminale 1964, WB Saunders, Philadelphia.
86. Smith J.S., Lal A., Harman-Smith M., et al. Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg 2007, 106:1034-1040.
87. Soyuer S., Chang E.L., Selek U., et al. Radiotherapy after surgery for benign cerebral meningioma. Radiother Oncol 2004, 71:85-90.
88. Stout A.P., Murray A.R. Hemangiopericytoma. A vascular tumor featuring Zimmerman's pericytes. Ann Surg 1942, 116:26-33.
89. Taylor B.W., Marcus R.B., Friedman W.A., et al. The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1988, 15:299-304.
90. Tishler R.B., Loeffler J.S., Lunsford L.D., et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993, 27:215-221.
91. Topp W.C., Lane D., Pollack R. Transformation by SV40 and polyomavirus. DNA Tumor Viruses 1981, 200-301. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. J. Tooze (Ed.).
92. Wada K., Maruno M., Suzuki T., et al. Chromosomal and genetic abnormalities in benign and malignant meningiomas using DNA microarray. Neurol Res 2005, 27:747-754.
93. Wellenreuther R., Kraus J.A., Lenartz D., et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 1995, 146:827-832.
94. Yano S., Kuratsu J. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg 2006, 105:538-543. Kumamoto Brain Tumor Research Group.
95. Zhang Z., Wang J., Muhr C., et al. Syngergistic inhibitory effects of interferon-alpha and 5-fluorouracil in meningioma cells in vitro. Cancer Lett 1996, 100:99-105.
96. Zhen H., Zhang X., Bu X., et al. Expression of the simian virus 40 large tumor antigen (Tag) and formation of Tag-p53 and Tag-pRb complexes in human brain tumors. Cancer 1999, 86:2124-2132.
97. Zimmerman R.D. MRI of intracranial meningiomas. meningiomas 1991, 62-69. Raven Press, New York. O. Al-Mefty (Ed.).